News

13 Jan 2017

CEO Dr David Bunton: Finalist - Annual Life Science Award 2017

ReproCELL Europe Ltd's CEO, Dr David Bunton, is one of the finalists nominated for the Life Science Business Leadership Award, part of Scotland's Annual Life Science Awards and Dinner, 2017.
Read More >>

22 Nov 2016

Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products

ReproCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical trials conducted by Healios, as well as the formation of said contract on the same day.
Read More >>

16 Nov 2016

Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.
Read More >>

14 Nov 2016

Joint enterprise - Development of Drug Discovery Applications Using Neurons Derived from iPS Cells

Joint Enterprise of Keio University and Juntendo University - Notice regarding inclusion in Relevant Leading Businesses to Receive Assistance in the Special District of Yokohama City for the project of Development of Drug Discovery Applications Using Neurons Derived from iPS Cells
Read More >>

1 2 3 4 >>

Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

16/11/2016

Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.

1. Details of entrustment contract

 

As per this contract, FANCL will develop a multi-component cell culture model system derived from human iPS cells in collaboration with ReproCELL and employ the technology to focus on anti-aging drug development. FANCL researches, develops, manufactures, and sells cosmetics and nutritional supplements; in the future, FANCL will use the cell technology to advance its basic research and product development.

 

Human iPS cells hold great promise not only for regenerative medicine, but as a tool for product development applicable to a variety of fields. A key strategy of ReproCELL is to apply the accumulated corporate human iPS cell know-how to development innovative tools for use in a variety of medical and other business applications.


2. Schedule

 

Date of contract formation and business start date: November 16, 2016

 

3. Partner overview
 

(1) Name FANCL Corp.
(2) Location 89-1 Yamashita-chou, Naka-ku, Yokohama
(3) Name & position of representative Representative Director and President/CEO Kazuyoshi Miyajima
(4) Business activities Research, development, manufacture, and sales of cosmetics, supplements, and health foods
(5) Capital Stock 10,795,000,000 yen
(6) Date founded August 18, 1981
(7) Major stockholders and percentage of stock held KI Corp. (13.05%)
Kenji Ikemori (8.76%)


End.

Live chat by BoldChat